<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83307">
  <stage>Registered</stage>
  <submitdate>28/10/2008</submitdate>
  <approvaldate>12/11/2008</approvaldate>
  <actrnumber>ACTRN12608000576325</actrnumber>
  <trial_identification>
    <studytitle>Randomised trial of anti-emetics in pre-hospital care (The RAPS Trial)</studytitle>
    <scientifictitle>In prehospital patients which antiemetic agent (maxolon, midazoloam or ondansetron) is superior in reducing nausea and vomiting</scientifictitle>
    <utrn />
    <trialacronym>Randomised trial of Antiemetics in the Prehospital Setting (RAPS Trial)</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Nausea and vomiting</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Conditions of unknown or disputed aetiology (such as chronic fatigue syndrome/myalgic encephalomyelitis)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients to receive either
Ondansetron 4mg intramuscular injection
Midazolam  2.5mg intramuscular injection

These agents will be administered as a one off single intramuscular (IMI) injection.  Followup will be continued until the patient has arrived at hospital - usually within 30 - 40 minutes.</interventions>
    <comparator>Patients to receive:
Maxolon 10mg intramuscular injection

This agent will be administered as a one off single IMI injection.  Followup will be continued until the patient has arrived at hospital - usually within 30 - 40 minutes.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Reduction in nausea and vomiting. 
Active vomiting will be assessed by direct observation of the patient. 
Nausea will be assessed using a verbal analogue scale (Rating scale of 1 - 10).</outcome>
      <timepoint>On arrival at hospital Emergency Departments</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Significant adverse events will be assessed through either direct observation by the attending ambulance paramedic or observed / reported by clinical staff at the receiving hospital.</outcome>
      <timepoint>On arrival at hospital Emergency Departments</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>All patients managed by the ambulance service who are either actively vomiting or have a nausea score greater or equal to 4</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Age less than 18
Received trial agents in the previous 24hours
Pregnant or possibly pregnant
Weight less than 60kg
Altered conscious level (Glascow Coma Score &lt; 15)
Refuses intramuscular injection
No consent</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Patients identified by treating ambulance  paramedics suitable for inclusion.  Exclusion criteria assessed.  Trial drug ampoules identical and labeled with trial number.</concealment>
    <sequence>Computerised random number generator undertaken by the manufacturing pharmacist</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>7/11/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>450</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>St John Ambulance - Western Australian Ambulance Service</primarysponsorname>
    <primarysponsoraddress>Great Eastern Highway
Belmont 6104
Western Australia</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>St John Ambulance - Western Australian Ambulance Service</fundingname>
      <fundingaddress>209 Great Eastern Highway
Belmont 6104
Western Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>University</othercollaboratortype>
      <othercollaboratorname>Emergency Medicine - University of Western Australia</othercollaboratorname>
      <othercollaboratoraddress>M516
35 Stirling Hwy
Crawley 6009
Western Australia</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>There is little evidence that indicates which anti-emetic (a drug to treat nausea and vomiting) is most effective in the Emergency and pre-hospital setting despite the widespread clinical use of the agents. The aim of this study is to undertake a randomised controlled trial in the pre-hospital setting to evaluate the efficacy of 3 commonly used anti-emetics.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of Western Australia</ethicname>
      <ethicaddress>35 Stirling Hwy
Crawley 6009
Western Australia</ethicaddress>
      <ethicapprovaldate>7/11/2008</ethicapprovaldate>
      <hrec>RA/4/1/2167</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Associate Professor Ian Jacobs</name>
      <address>Univeristy of Western Australia
35 Stirling Hwy 
Crawley 6009
Western Australia</address>
      <phone>+61 8 9346 4354</phone>
      <fax>+61 8 9346 1665</fax>
      <email>ian.jacobs@uwa.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Associate Professor Ian Jacobs</name>
      <address>Emergency Medicine (M516)
University of Western Australia
35 Stirling Hwy 
Crawley 6009</address>
      <phone>+61 8 9346 4354</phone>
      <fax>+ 61 8 9346 1665</fax>
      <email>ian.jacobs@uwa.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Associate Professor Ian Jacobs</name>
      <address>University of Western Australia
35 Stirling Hwy 
Crawley 6009
Western Australia</address>
      <phone>+61 8 9346 4354</phone>
      <fax>+61 8 9346 1665</fax>
      <email>ian.jacobs@uwa.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>